secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2022-03-18T23:59:59+00:00
Accession:  0001193125-22-079036
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences appoints Barbara K. Finck, M.D. to Board of Directors
-----------------------------------------------------------------------

- Appointment effective March 16, 2022; Dr. Finck will serve as a Class I director until 2024 annual meeting.
- Annual cash retainer of $40,000, paid quarterly in arrears on a pro-rata basis.
- Granted option for 50,000 shares of common stock vesting monthly over three years.
- Dr. Finck currently acting Chief Medical Officer at Coherus BioSciences; prior CMO at NKT Therapeutics and Osprey Pharmaceuticals.
- No arrangement with any other person for election; no family relationships with directors or officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312522079036/0001193125-22-079036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312522079036/d322296d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-079036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer